Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update
Acurx Pharmaceuticals, Inc. (ACXP)
Company Research
Source: PR Newswire
STATEN ISLAND, N.Y., Feb. 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its full year and fourth quarter 2025 financial results on Friday, March 13, 2026 at 8:00 am ET before the U.S. financial markets open.David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:Date: Friday, March 13, 2026 Time: 8:00 a.m. ET Toll free (U.S.): 877-790-1503 Access ID: 13758852Click here for participant International Toll-Free access numbers About IbezapolstatIbezapolstat is the Company's lead antibiotic candidate preparing for international Phase 3 clinical trials to treat patients with C
Show less
Read more
Impact Snapshot
Event Time:
ACXP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACXP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACXP alerts
High impacting Acurx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ACXP
News
- Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update [Yahoo! Finance]Yahoo! Finance
- USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors [Yahoo! Finance]Yahoo! Finance
- USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC InhibitorsPR Newswire
- Acurx Pharmaceuticals (NASDAQ:ACXP) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ACXP&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Acurx Pharmaceuticals (NASDAQ:ACXP) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ACXP&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall SMarketBeat
ACXP
Earnings
- 11/12/25 - Beat
ACXP
Sec Filings
- 2/12/26 - Form EFFECT
- 2/11/26 - Form 424B3
- 2/2/26 - Form S-1
- ACXP's page on the SEC website